Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Sanofi Pasteur Obtains License from Syntiron to Develop & CommercializeVaccine to Prevent Staphylococcus Infections

By Pharmaceutical Processing | December 16, 2009

Sanofi Pasteur, the vaccinesdivision of the sanofi-aventis Group, announced today that it has entered intoan exclusive, world-wide licensing agreement with Syntiron to develop andcommercialize its prophylactic vaccine against Staphylococcus, includingMethicillin-Resistant Staphylococcus aureus or MRSA. MRSA are responsible forseveral difficult-to-treat infections in humans, sometimes referred to asmultidrug-resistant Staphylococcus aureus because these bacteria are resistantto a large group of antibiotics, including penicillins. Syntiron is a private biotech company located in St. Paul, Minnesota; itsmission is the prevention and treatment of human disease resulting frombacterial infection. Under the terms of the agreement, Sanofi Pasteur willsupport the joint, pre-clinical development of the product, workingcooperatively with Syntiron, and be responsible for all future developments,regulatory approval, and commercialization of the vaccine. The agreementincludes an undisclosed initial licensing fee, milestone payments, and royaltypayments on future sales of the product. “This agreement with Syntiron is just another example of Sanofi Pasteur’sinterest in partnering with biotechs to produce innovative vaccines to addresspublic health needs,” said Wayne Pisano, President and Chief Executive Officeof Sanofi Pasteur. “Along with our development of a vaccine to preventClostridium difficile infection, the successful development of a vaccine toprevent MRSA would be a major achievement in combating hospital-associatedinfections.”

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards